- World rank, all time
- #28,884 of 42,892
- Rank in Japan
- #1,173 of 2,112
- Research works
- 259 ▲ 69% vs 2013–17
- Citations
- 7.1k 27.4 per fractional work
- Top-10% rate
- 7.4% record average 16.5%
- Open access
- 67% world 28%
What is Bristol-Myers Squibb (Japan) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Health SciencesDomain | #17,161 of 20,462 | 19.6% | 124 |
Each strip is that field’s whole ranked pool, with the notch where Bristol-Myers Squibb (Japan) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.1×. Every wedge is a field page.
- Immunology and Microbiology 5.1×
- Pharmacology, Toxicology and Pharmaceutics 4.7×
- Medicine 2.7×
- Mathematics 2.3×
- Chemistry 2.3×
- Economics, Econometrics and Finance 2.1×
- Biochemistry, Genetics and Molecular Biology 1.8×
- Veterinary 1.5×
- Neuroscience 1.3×
- Dentistry 1.1×
- Agricultural and Biological Sciences 0.8×
- Health Professions 0.6×
- Engineering 0.5×
- Nursing 0.4×
- Computer Science 0.3×
- Decision Sciences 0.2×
- Environmental Science 0.2×
- Social Sciences 0.1×
- Psychology 0.1×
- Physics and Astronomy 0.1×
Who are the top researchers at Bristol-Myers Squibb (Japan)?
Ranked on the composite score, TOSHIKAZU OKI, Hideo Kamei and Takeo Miyaki lead among researchers whose main affiliation is Bristol-Myers Squibb (Japan).
- 1 TOSHIKAZU OKI Japan · #105,821 worldwide 283 citations · 41 works
- 2 Hideo Kamei Japan · #193,124 worldwide 75 citations · 27 works
- 3 Takeo Miyaki Japan · #392,696 worldwide 146 citations · 15 works
Which keywords describe research at Bristol-Myers Squibb (Japan)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Epidemiology, Tumor Microenvironment, Lymphoma, Heart Failure, Prognostic Factors, Quality of Life, Cardiovascular Risk and Immunotherapy.
- Inflammatory Bowel Disease
- Proteasome Inhibitors
- Guidelines
- Treatment
- Prognostic Factors
- Heart Failure
- Cancer
- Tumor Microenvironment
- Inflammation
- Epidemiology
- Quality of Life
- Lymphoma
- Clinical Trials
- Immunotherapy
- Cardiovascular Risk
- Diagnosis
- Leukemia
- Genetic Mutations
- Pathogenesis
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 19 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 19 words, with their numbers
- Epidemiology3▲ 2.6×14 topics
- Inflammation2▲ 2.8×13 topics
- Quality of Life2▲ 3.8×6 topics
- Tumor Microenvironment2▲ 12×5 topics
- Lymphoma1▲ 27×3 topics
- Cancer1▲ 3.2×10 topics
- Clinical Trials1▲ 6.0×6 topics
- Heart Failure1▲ 9.6×5 topics
- Immunotherapy1▲ 5.9×6 topics
- Prognostic Factors1▲ 9.3×5 topics
- Cardiovascular Risk1▲ 12×3 topics
- Treatment1▲ 3.2×8 topics
- Diagnosis1▲ 3.8×8 topics
- Guidelines1▲ 7.3×4 topics
- Leukemia1▲ 42×2 topics
- Proteasome Inhibitors1▲ 47×2 topics
- Genetic Mutations1▲ 7.3×3 topics
- Inflammatory Bowel Disease1▲ 28×4 topics
- Pathogenesis1▲ 6.4×5 topics
Which research topics does Bristol-Myers Squibb (Japan) publish most on?
By volume in 2022–2025: Multiple Myeloma Research and Treatments, Cancer Immunotherapy and Biomarkers, Health Systems, Economic Evaluations, Quality of Life and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Multiple Myeloma Research and Treatments Hematology 1 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
- 4 CAR-T cell therapy research Oncology 1 works
- 5 Acute Myeloid Leukemia Research Hematology 1 works
- 6 Cardiomyopathy and Myosin Studies Cardiology and Cardiovascular Medicine 1 works
- 7 Cardiovascular Function and Risk Factors Cardiology and Cardiovascular Medicine 1 works
- 8 Inflammatory Bowel Disease Genetics 1 works
- 9 Heart Failure Treatment and Management Cardiology and Cardiovascular Medicine 1 works
- 10 Spondyloarthritis Studies and Treatments Rheumatology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Bristol-Myers Squibb (Japan)'s research output changed?
Output in 2018–2022 was 69% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Tokyo
- The University of Tokyo
- Tokyo Institute of Technology
- Keio University
- Waseda University
- Tokyo University of Science
- Nihon University
- Hitachi (Japan)
- NTT (Japan)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.